PHAXIAM Therapeutics S.A.
PHXM · NASDAQ
12/31/2023 | 9/30/2023 | 6/30/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | – | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$0 | $0 | – | -$0 |
| % Margin | – | – | – | – |
| EBITDA | -$0 | -$0 | – | -$0 |
| % Margin | – | – | – | – |
| Net Income | -$0 | -$0 | – | $0 |
| % Margin | – | – | – | – |
| EPS Diluted | -1.72 | 0 | – | 0.19 |
| % Growth | – | – | – | – |
| Operating Cash Flow | -$0 | – | – | -$0 |
| Capital Expenditures | -$0 | – | – | -$0 |
| Free Cash Flow | -$0 | – | – | -$0 |